Patients
SENTINEL NODE, DISEASE, PATHOLOGY, INVASIVE BREAST CANCER
Patients in the prospective study (ClinicalTrial.gov NCT05609058, 08/11/2022) who underwent breast-conserving surgery and sentinel node biopsy or axillary dissection, and pathology confirmed invasive breast cancer with no residual microscopic disease from four nationwide centers in China were included.Between Jan 2019 and Oct 2020, a total of 230 patients from four nationwide centers in China were screened, of whom 208 in one center were enrolled for DL modeling and were divided into the training cohort (